In this study the investigators use clinical, biological and imaging markers to develop
predictive markers for remission from depression. The investigators compare individuals who
have received placebo to individuals who have received 10 mg of escitalopram for one week. In
this double-blind, randomized study the investigators a) compare the groups to observe the
short-term effects of escitalopram and b) study the predictive value of these observations
with respect to remission. Measures include, but are not restricted to, limbic emotional
reactivity as assessed by fMRI, emotional processing, emotional memory, autobiographical
memory.